These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30180593)

  • 1. Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles.
    Li F; Zhang H; He M; Liao J; Chen N; Li Y; Zhou S; Palmisano M; Yu A; Pai MP; Yuan H; Sun D
    Mol Pharm; 2018 Oct; 15(10):4505-4516. PubMed ID: 30180593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration.
    Chen N; Brachmann C; Liu X; Pierce DW; Dey J; Kerwin WS; Li Y; Zhou S; Hou S; Carleton M; Klinghoffer RA; Palmisano M; Chopra R
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):699-712. PubMed ID: 26231955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of Total and Unbound Paclitaxel After Administration of Paclitaxel Micellar or Nab-Paclitaxel: An Open, Randomized, Cross-Over, Explorative Study in Breast Cancer Patients.
    Borgå O; Lilienberg E; Bjermo H; Hansson F; Heldring N; Dediu R
    Adv Ther; 2019 Oct; 36(10):2825-2837. PubMed ID: 31432461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neonatal Fc Receptor (FcRn) Enhances Tissue Distribution and Prevents Excretion of nab-Paclitaxel.
    Li F; Yuan H; Zhang H; He M; Liao J; Chen N; Li Y; Zhou S; Palmisano M; Yu A; Pai M; Sun D
    Mol Pharm; 2019 Jun; 16(6):2385-2393. PubMed ID: 31002261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Penetration of Paclitaxel in Abdominal Wall of Rabbits after Hyperthermic Intraperitoneal Administration of Nab-Paclitaxel Compared to Standard Paclitaxel Formulation.
    Coccolini F; Acocella F; Morosi L; Brizzola S; Ghiringhelli M; Ceresoli M; Davoli E; Ansaloni L; D'Incalci M; Zucchetti M
    Pharm Res; 2017 Jun; 34(6):1180-1186. PubMed ID: 28247168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of drug formulations on kinetics and toxicity in a preclinical model of paclitaxel-induced neuropathy.
    Klein I; Wiesen MHJ; Albert V; Bobylev I; Joshi AR; Müller C; Lehmann HC
    J Peripher Nerv Syst; 2021 Jun; 26(2):216-226. PubMed ID: 33683765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.
    Neesse A; Frese KK; Chan DS; Bapiro TE; Howat WJ; Richards FM; Ellenrieder V; Jodrell DI; Tuveson DA
    Gut; 2014 Jun; 63(6):974-83. PubMed ID: 24067278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic sensitivity of paclitaxel to its delivery vehicles drives distinct clinical outcomes of paclitaxel formulations.
    Li Y; Chen N; Palmisano M; Zhou S
    Mol Pharm; 2015 Apr; 12(4):1308-17. PubMed ID: 25714793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulating paclitaxel in nanoparticles alters its disposition.
    Yeh TK; Lu Z; Wientjes MG; Au JL
    Pharm Res; 2005 Jun; 22(6):867-74. PubMed ID: 15948030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.
    Gardner ER; Dahut WL; Scripture CD; Jones J; Aragon-Ching JB; Desai N; Hawkins MJ; Sparreboom A; Figg WD
    Clin Cancer Res; 2008 Jul; 14(13):4200-5. PubMed ID: 18594000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo pharmacokinetics, biodistribution and anti-tumor effect of paclitaxel-loaded targeted chitosan-based polymeric micelle.
    Rezazadeh M; Emami J; Hasanzadeh F; Sadeghi H; Minaiyan M; Mostafavi A; Rostami M; Lavasanifar A
    Drug Deliv; 2016 Jun; 23(5):1707-17. PubMed ID: 25188785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Development of Oral Taxane Formulations: A Review.
    Chowdhury N; Singh M
    Crit Rev Ther Drug Carrier Syst; 2020; 37(3):205-227. PubMed ID: 32749138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein nanoparticles as drug carriers in clinical medicine.
    Hawkins MJ; Soon-Shiong P; Desai N
    Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
    Petrelli F; Borgonovo K; Barni S
    Expert Opin Pharmacother; 2010 Jun; 11(8):1413-32. PubMed ID: 20446855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review.
    Stage TB; Bergmann TK; Kroetz DL
    Clin Pharmacokinet; 2018 Jan; 57(1):7-19. PubMed ID: 28612269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel.
    Chen N; Li Y; Ye Y; Palmisano M; Chopra R; Zhou S
    J Clin Pharmacol; 2014 Oct; 54(10):1097-107. PubMed ID: 24719309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of paclitaxel-containing liposomes in rats.
    Fetterly GJ; Straubinger RM
    AAPS PharmSci; 2003 Nov; 5(4):E32. PubMed ID: 15198520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
    Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
    Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing intratumoral biodistribution and antitumor activity of nab-paclitaxel through combination with a vascular disrupting agent, combretastatin A-4-phosphate.
    Gao M; Zhang D; Yao N; Jin Q; Jiang C; Zhang J; Wang F
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1187-1194. PubMed ID: 31520101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics and Exposure-Response Analysis of nab-Paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors.
    Li Y; Kassir N; Chen N; Wang X; Palmisano M; Zhou S
    Clin Pharmacol Drug Dev; 2021 Feb; 10(2):115-130. PubMed ID: 32459889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.